Skip to content
HowShorted

TransMedics Group, Inc. short interest in 2025

In 2025, TransMedics Group, Inc.'s disclosed short interest ran from 26.79% of shares outstanding on 15 Jan 2025 to 21.07% on 31 Dec 2025, a change of -5.72 percentage points. The year's high was 33.06% on 31 Jan 2025 and its low 20.08% on 14 Nov 2025, averaging 24.77% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 12.50 days on 31 Mar 2025. Full history: TransMedics Group, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for TransMedics Group, Inc. in 2025

2025 in figures

Start of year
26.79% (15 Jan 2025)
End of year
21.07% (31 Dec 2025)
Change
-5.72 pp
High
33.06% (31 Jan 2025)
Low
20.08% (14 Nov 2025)
Average
24.77%
Highest days to cover
12.50 (31 Mar 2025)
SEC filings marked
8

Every report in 2025

TransMedics Group, Inc. short interest in 2025
SettlementShort interestDays to coverFilings since previous
15 Jan 202526.79%2.28
31 Jan 202533.06%6.19
14 Feb 202531.96%8.66
28 Feb 202527.72%5.5410-K filed, results (8-K)
14 Mar 202528.37%8.88
31 Mar 202528.15%12.50
15 Apr 202526.09%6.65
30 Apr 202526.00%8.54
15 May 202523.95%5.2810-Q filed, results (8-K)
30 May 202523.89%11.67
13 Jun 202523.23%10.11
30 Jun 202523.78%8.76
15 Jul 202523.63%8.83
31 Jul 202522.50%5.5810-Q filed, results (8-K)
15 Aug 202523.00%6.52
29 Aug 202524.26%11.50
15 Sep 202524.62%6.97
30 Sep 202523.89%9.19
15 Oct 202523.38%9.21
31 Oct 202522.07%6.5410-Q filed, results (8-K)
14 Nov 202520.08%8.72
28 Nov 202522.58%8.03
15 Dec 202520.47%9.05
31 Dec 202521.07%11.38

See also: TransMedics Group, Inc.'s full history · most shorted US stocks of 2025 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.